A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

Inclusion Criteria: * Screening laboratory result indicating hepatitis C virus (HCV) Genotype 1, 2, 4, 5 or 6 (GT1,2,4,5,6) infection * Chronic HCV infection * Subject must be HCV treatment-naïve or have failed prior HCV treatment * Subject must have documented compensated cirrhosis and no current or past clinical evidence of decompensated liver disease Exclusion Criteria: * Positive test result at screening for Hepatitis B surface antigen or anti-human immunodeficiency virus (anti-HIV) antibody * HCV genotype performed during screening indicating co-infection with more than 1 HCV genotype * Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT-493/ABT-530